Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gorson, K. C.
Right arrow Articles by Ropper, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gorson, K. C.
Right arrow Articles by Ropper, A. H.
Related Collections
Right arrow Chronic inflammatory demyelinating polyneuropathy
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrowRelated Article
NEUROLOGY 2004;63:715-717
© 2004 American Academy of Neurology
Brief Communications

Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy

Kenneth C. Gorson, MD, Anthony A. Amato, MD and Allan H. Ropper, MD

From the Division of Neurology (Drs. Gorson and Ropper), St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA; and Department of Neurology (Dr. Amato), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.

Address correspondence and reprint requests to Dr. Kenneth C. Gorson, Division of Neurology, St. Elizabeth’s Medical Center, 736 Cambridge Street, Boston, MA 02135; e-mail: kengorson{at}comcast.net

The authors retrospectively reviewed the efficacy of mycophenolate mofetil (MMF; mean dose, 2 g/day given for an average of 14 months) in 21 patients with immune demyelinating polyneuropathy. There were no significant differences in the median strength, sensory, or Rankin scores before and after treatment. In patients with immunoglobulin (Ig) M neuropathy, the M-protein decreased by 22%. Three patients with chronic inflammatory demyelinating polyneuropathy (30%) and one patient with IgM neuropathy (13%) improved. The authors found that MMF induced a modest benefit in ~20% of their patients and stabilized patient condition, allowing reduction of steroid or IVIg therapy.

Received February 11, 2004. Accepted in final form April 14, 2004.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the August 24 issue to find the link for this article.


Related Article

August 24 Highlights
Neurology 2004 63: 604-605. [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.